Source: FDA, National Drug Code (US) Revision Year: 2020
Veregen is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
The safety and effectiveness of Veregen have not been established for treatment beyond 16-weeks or for multiple treatment courses.
The safety and effectiveness of Veregen in immunosuppressed patients have not been established.
Veregen is to be applied three times per day to all external genital and perianal warts.
Apply about an 0.5 cm strand of the Veregen to each wart using the finger(s), dabbing it on to ensure complete coverage and leaving a thin layer of the ointment on the warts. Patients should wash their hands before and after application of Veregen.
It is not necessary to wash off the ointment from the treated area prior to the next application.
Veregen is not for ophthalmic, oral, intravaginal, or intra-anal use.
Treatment with Veregen should be continued until complete clearance of all warts, however no longer than 16 weeks.
Local skin reactions (e.g. erythema) at the treatment site are frequent. Nevertheless, treatment should be continued when the severity of the local skin reaction is acceptable.
Prior to dispensing to the patient, store refrigerated 2°C to 8°C (36°F to 46°F). After dispensing, store refrigerated or up to 25°C (77°F). Do not freeze.
KEEP OUT OF THE REACH OF CHILDREN.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
